To design novel lead molecules for the enzyme, AChE associated with Alzheimer's disease

International Journal of Pharmaceutical Sciences Review and Research

Volumn 22, Issue 2, 2013, Pages 296-302

  Yellamma, Kuna ^a   Nagaraju, Sake ^a   Peera, Kutagolla ^a   Praveen, Kukkarasapalli ^a  

^a SRI VENKATESWARA UNIVERSITY   (India)

Author keywords

Acetylcholinesterase; Alzheimer's disease (AD); Galantamine analogues; Lead molecules

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; CHOLINESTERASE INHIBITOR; GALANTAMINE; ZINC;

ALZHEIMER DISEASE; ARTICLE; BINDING AFFINITY; CHOLINESTERASE INHIBITION; DRUG DATABASE; DRUG DESIGN; DRUG SELECTIVITY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME BINDING; MOLECULAR DOCKING; PROTEIN STRUCTURE; PROTEIN TARGETING; SCORING SYSTEM;

EID: 84884952540     PISSN: 0976044X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Price, D.L., New perspectives on Alzheimer's disease, Neuroscience 9, 1986, 489-512.
2. Kasa P, Rakonczay Z, Gulya K,. The cholinergic system in Alzheimer's disease, Prog. Neurobiology, 52, 1997, 511-535.
3. Carvalho I, Pupo MT, Borges A. D. L, Bernardes, The asymmetric deformation of CH3 groups, was 1510cm-1 and the values, L. S. C. Quím Nova, 26, 2003, 428-438.
4. Kawakami Y, Inoue A T, Kawai T, Wakita T M, Sugimoto H, Hop finger, The rational for E2020 as a potent acetyl cholinesterase inhibitor, A. J. Bioorg. Med. Chem. 4, 1996, 1429-1446.
5. Davies P, Maloney A. J, loss of central cholinergic neurons in Alzheimer's disease, Lancet, 2, 1976, Selective 1403.
6. Sims NR, Bowen DM, Allen S. J, Smith CC, Neary D, Thomas DJ, Presynaptic cholinergic dysfunction in patients with dementia, J. Neurochem., 40, 1983, 503-509.
7. DeKosky ST, Harbaugh RE, Schmitt FA, Bakay RA, Chui HC, Knopman DS, Cortical biopsy in Alzheimer's disease: diagnostic accuracy and Neurochemical, neuropath logical and cognitive correlations, Ann. Neurol. 32, 1992, 625-632.
8. Whitehouse PJ, Cholinergic therapy in dementia, Acta Neurol. 149, 1993, 42-45.
9. Kelly CA, Harvey RJ, Cayton H, Drug treatments for Alzheimer's disease, Br. Med. J. 314, 1997, 693-694.
10. Scott LJ, Goa KL, Galantamine: a review of its use in Alzheimer's disease, Drugs, 60, 2000, 1095-1122.
11. Gottwald MD, Rozanski RI, Rivastigmine a brain region selective acetyl cholinesterase inhibitor for treating Alzheimer's disease: review and current status, Expert Opin. Invest, Drugs, 8, 1999, 1673-1682.
12. Sussman JL, Harel M, Frolow F, Oefner C, Goldman A, Toker L, Atomic structure of acetyl cholinesterase from Torpedo California: a prototypic acetylcholinebinding protein Silman I Science, 253, 1991, 872-879.
13. Koellner G, Kryger G, Millard CB, Silman I, Sussman JL, Steiner T, Properties of water molecules in the active site gorge of acetyl cholinesterase from computer simulation, J. Mol. Biol., 296, 2000, 713-735.
14. Harel M, Schalk I, Ehret-Sabatier L, Bouet F, Goeldner M, Hirth C, Axelsen PH, Silman I, Sussman JL, Structure and dynamics of the active site gorge of acetyl cholinesterase: synergistic use of molecular dynamics simulation and X-ray crystallography, Proc Natl Acad Sci USA 90,1993,9031-9035.
15. Kryger G, Silman I, Sussman JL, Structure of acetyl cholinesterase complexes with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs, Structure, 7, 1999, 297-307.
16. Bartolucci C, Perola E, Cellai L, Brufani M and Lamba D, "Back door" opening implied by the crystal structure of a carbamoylated Acetyl cholinesterase, Biochemistry, 38, 1999, 5714-5719.
17. Giacobin E, Cholinergic foundations of Alzheimer's disease therapy, J. Physiol., Paris 92, 1998, 283-287.
18. Dal-Bianco P, Maly J, Wober C, Lind C, Koch G, Hufgard J, Marschall I, Mraz M and Deecke L, Galantamine treatment in Alzheimer's disease, J. neural Transmission, 33, 1991, 59-63.
19. Thomsen T., Bickel U., Fischer J. P. and Kewitz H, Galantamine hydro bromide in a long-term treatment of Alzheimer's disease. Dementia 1, 1990, 46-51.
20. Wilcock GK, Scott M, Pearsall T, Neubauer K, Boyle M, and Razay G. Galantamine and the treatment of Alzheimer's disease, Int. J. geriatric. Psychiat. 8, 1993, 781-782.
21. Wilkinson D, Clinical experience with Donepezil (Aricept) in the UK, J. neural Transmission, 54, 1998, 311-315.
22. Proskurnina NF and Yakovleva A P, Alkaloids of Galan thus woronowi. II. Isolation of new alkaloid, J. gen. Chemistry, 22, 1952, 1899-1902.
23. Irwin RL and Smith HJ, Cholinesterase inhibition by Galantamine and lycoramine, Biochemical Pharmacy, 3, 1960, 147-148.
24. Thomsen T, Kewitz H, Selective inhibition of human AChE by Galantamine in vitro and in vivo. Life Sciences, 46, 1990, 1553-1558.
25. Schrattenholz A, Pereira EF, Roth U, Weber KH, Albuquerque EX, Maelicke A (Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting lignads, Mol Pharmacology, 49, 1996,1-6.
26. Albuquerque EX, Alkondon M, Pereira EF, Castro NG, Schrattenholz A, Barbosa CT, Bonfante-Cabarcas R, Aracava Y, Eisenberg HM, Maelicke A Properties of neuronal nicotinic acetylcholine receptors: pharmacological characterization and modulation of synaptic function, J Pharmacol Exp Ther, 280, 1997, 1117-1136.
27. Maelicke A, Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease, Dement Geriatric Cogn Disord, 11, 2000, 11-18.
28. Raskind MA, Peskind ER, Wessel T, Yuan W, Galantamine USA-1Study Group Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension, Neurology, 54, 2000, 2261-2268.
29. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld, Ding CA 5-Month, randomized, placebocontrolled trial of Galantamine in AD, The Galantamine USA-10 Study Group. Neurology 54: 2000, 2269-2276.
30. Wilcock GK, Lilienfeld S, Gaens E (Efficacy and safety of Galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomized controlled trial, Galantamine International-1 Study Group Br Med J, 321, 2000, 1445-1449.
31. Berman HM, john w, Zukang F, Gary G, Bhat TN, Helge W, Ilya NS and Philip EB, The protein Data Bank, Nucleic Acids research, 28(1), 2000, 235-242.
32. Inestrosa NC, Alvarez A, Perez CA, Moreno RD, Vicente M, Linker C, Casanueva OI, Soto C, Garrido J Neuron, 16, 1996, 881-891.
33. Alvarez A, Opazo C, Alarcòn R, Garrido J, Inestrosa NC, Amyloid-cholinesterase interactionsImplications for Alzheimer's disease, J. Mol. Biol., 272, 1997,348-361.
34. Sweeney JE, Bachman ES, Coyle JT Effects of different doses of Galantamine, a long-acting acetylChE inhibitor, on memory in mice, Psychopharmacology, 102, 1990, 191-200.